Back to results
US 2004/0082631 A1Published application
Pyrazole compositions useful as inhibitors of ERK
AssigneeVertex Pharmaceuticals Incorporated
InventorsMichael Hale, James Janetka, Francois Maltais
Life of this patent
Estimating the term…
Abstract
Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1 where R1, R2, T and Ht are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
Claims27
A compound of formula I:
- 43
- or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
- Ht is a heterocyclic ring selected from pyrazol-3-yl, [1,2,4]triazol-3-yl, [1,2,3]triazol-4-yl, or tetrazol-5-yl, said pyrazol-3-yl having R3 and QR4 substituents, and said [1,2,4]triazol-3-yl or [1,2,3]triazol-4-yl substituted by either R3 or QR4;
- R1 is selected from R, F, Cl, N(R )2, OR, NRCOR, NRCON(R8)2, CON(R8)2, SO2R, NRSO2R, or SO2N(R8)2;
- T is selected from a valence bond or a linker group;
- each R is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons;
- R2 is selected from hydrogen, CN, halogen, or an optionally substituted group selected from aryl, aralkyl, heteroaryl, heterocyclyl, acyclic aliphatic chain group having one to six carbons, or a cyclic aliphatic group having three to ten carbons;
- R3 is selected from R, OH, OR, N(R8)2, F, Cl, or CN;
- Q is a valence bond, J, or an optionally substituted C1-6 alkylidene chain wherein up to two nonadjacent carbons of the alkylidene chain are each optionally and independently replaced by J;
- J is selected from —C(═O)—, —CO2—, —C(O)C(O)—, —NRCONR8—, —N(R)N(R8)—, —C(═O)NR8—, —NRC(═O)—, —O—, —S—, —SO—, —SO2—, —N(R)O—, —ON(R8)—, —OC(═O)N(R8)—, —N(R)COO—, —SO2N (R8)—, —N(R)SO2—, or —N(R8)—;
- R4 is selected from —R8, —R5, —NH2, —NHR5, —N(R5)2, or —NR5 (CH2)yN (R5)2;
- each R5 is independently selected from R6, R7, —(CH2)yCH(R6) (R7) , —(CH2)yR6, —(CH2)yCH(R6)2, —(CH2)yCH(R7)2, or —(CH2)yR7;
- y is 0-6;
- each R6 is an optionally substituted group independently selected from an aliphatic, aryl, aralkyl, aralkoxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, heterocyclyl, heterocyclylalkyl, or heterocyclylalkoxy, group;
- each R7 is independently selected from an optionally substituted aliphatic, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, or alkoxycarbonyl;
- each R8 is independently selected from R or two R8 on the same nitrogen taken together with the nitrogen optionally form a four to eight membered, saturated or unsaturated heterocyclic ring having one to three heteroatoms;
- and each substitutable ring nitrogen is independently substituted by R, NR2, COR, CO2(C1-C6 optionally substituted alkyl), SO2(C1-C6 optionally substituted alkyl), CONR2, or SO2NR2;
- provided that:
- (a) TR2 and QR4 are not the same;
- (b) TR2 and R3 are not the same;
- (c) when Ht is tetrazol-5-yl and R1 is methyl, then TR2 is other than hydrogen;
- (d) when Ht is [1,2,3]triazole-4-yl and R1 and R3 are both methyl, then TR2 is other than hydrogen;
- and (e) when Ht is pyrazol-3-yl and R1 and R3 are both hydrogen, then TR2 is other than methyl when QR4 is phenyl in the 4-position;.
20 more elements
Dependencies are inferred from the claim text.